Go Back To Menu
Multimodal modern oncology treatments (surgery, radiotherapy, chemotherapy, targeted therapy, immunotherapy) can extend patients’ survival time. However, clinically many patients still face tumor recurrence, metastasis and deteriorated quality of life after treatment. The root cause lies in the fact that conventional therapies focus solely on tumors themselves and pay insufficient attention to repairing treatment-induced immune imbalance. United Life’s "NK Immune Reconstitution Program" is developed based on this philosophy. Centered on NK cells (natural killer cells), it combines patient condition assessment, immune microenvironment conditioning and long-term health management strategies to deliver a systematic long-term immune support regimen for cancer patients and high-risk populations.
NK cells (natural killer cells) form the first line of defense of the human immune system. They can recognize and eliminate tumor cells and virus-infected cells without prior activation. In healthy individuals, NK cells patrol the body continuously to inhibit tumor formation and metastasis.
NK cells precisely eliminate tumor cells through four steps: "Recognition — Contact — Release — Induction of Apoptosis".
1. Recognition of Tumor Cells
Tumor cells usually lack surface markers or carry abnormal signals, which are rapidly targeted by NK cells.
2. Formation of Immunological Synapses
NK cells bind tightly to tumor cells to form a stable contact interface.
3. Release of Cytotoxic Granules
NK cells directionally secrete cytotoxic granules, delivering lethal substances into tumor cells and destroying their membrane structure.
4. Induction of Cell Apoptosis
Granzymes activate apoptotic signals inside tumor cells and trigger their death, with minimal impact on healthy normal cells.
When cancer patients lack sufficient NK cells, immune surveillance breaks down, allowing tumors to progress. NK cell therapy expands and activates NK cells ex vivo to optimize their quantity and activity before reinfusion to rebuild the body’s immune barrier. Compared with traditional chemo-radiotherapy, NK therapy does not rely on a single molecular target, delivers broad-spectrum anti-tumor effects, and causes milder systemic side effects.
● Patient Condition Assessment: Comprehensive evaluation to formulate personalized health management plans.
● NK Cell Immune Support: Activate and expand NK cells to boost immune surveillance and tumor-killing capacity.
● Tumor Microenvironment Modulation: Improve the tumor microenvironment, block immune suppression, and restore immune balance.
Compared with local conventional treatments that rely mainly on external tumor-killing effects, United Life’s NK therapy boasts advantages in therapeutic logic, side-effect control, cell quality and accessibility.
1. Therapeutic Logic
Local conventional treatment: Primarily external tumor elimination
United Life NK Program: Activate autologous immunity + synergistic tumor clearance
2. Side Effects
Local conventional treatment: Relatively severe, obvious damage to immune system
United Life NK Program: Generally mild, simultaneous repair of immune function
3. Cell Source
Local conventional treatment: N/A
United Life NK Program: Autologous / allogeneic cells with high-purity expansion
4. Combination Therapy Capacity
Local conventional treatment: Mainly monotherapy
United Life NK Program: Synergistic use with chemo-radiotherapy and targeted drugs for enhanced efficacy
5. Treatment Initiation Timeline
Local conventional treatment: Approximately 2–3 months from confirmed diagnosis to radiotherapy start
United Life NK Program: Treatment available within 7–16 days after assessment approval
1. Initial Clinical Assessment
Medical record review + eligibility judgment
2. Customized Regimen Design
Multidisciplinary MDT consultation
3. Cell Preparation
NK cell isolation + high-purity ex vivo expansion
4. Pass Quality Inspection
Cell reinfusion only after batch quality control passes.
5. Efficacy Monitoring
Immune biomarker testing + radiological assessment, dynamic regimen adjustment
Overseas patients often suffer hidden anxiety from uncertain medical procedures. United Life resolves this via a systematic full-cycle service system:
Pre-Treatment
Online preliminary medical record review, eligibility assessment completed within 24 hours
Multidisciplinary expert consultation to design personalized regimens
Assistance with visa, transportation and accommodation arrangements
During Treatment
Dedicated medical coordinator accompanies all appointments
Regular real-time condition updates for family members
Post-Treatment
Comprehensive treatment summary report and follow-up recommendations
Remote follow-up plan and fixed review schedule
1. Stage IV Cholangiocarcinoma Case
76-year-old Ms. Z diagnosed with moderately differentiated cholangiocarcinoma (T3N1M1 Stage IVA), complicated with pancreatic, transverse colon and liver metastasis plus portal vein tumor thrombus. She previously underwent two surgeries, multiple lines of chemotherapy (GC regimen, albumin-bound paclitaxel + gemcitabine, irinotecan + fluoropyrimidine), targeted therapy (dabrafenib + trametinib), and PD-1 combined low-dose chemotherapy.
She commenced United Life immunotherapy on September 18, 2024, for a total of 10 sessions at intervals of 7–21 days.
Treatment dates:
2024: Sep 18, Oct 1, Oct 10, Oct 22, Nov 13, Nov 27, Dec 10
2025: Jan 3, Jan 17, Feb 7
Key tumor markers fluctuated in early treatment phases and decreased significantly in later stages.
2. Stage IV Colorectal Cancer Case
51-year-old Mr. D diagnosed with moderately differentiated sigmoid colorectal cancer (T3N2M1 Stage IV), accompanied by multiple liver metastases, lung metastasis and peritoneal dissemination. He received primary tumor resection, first-line FOLFOX chemotherapy, second-line targeted combined chemotherapy (bevacizumab + cetuximab), then developed drug resistance accompanied by abdominal pain, fatigue, poor appetite and approximately 8kg weight loss.
He started United Life immunotherapy on May 20, 2024, receiving 10 sessions with 14–21 day intervals.
Treatment dates:
2024: May 20, Jun 3, Jun 17, Jul 1, Jul 15, Jul 29, Aug 12, Aug 26, Sep 9, Sep 23
The patient tolerated the full treatment course well without severe adverse reactions.
Q1. Who is eligible for NK cell therapy? Can late-stage cancer patients still receive this treatment?
NK cell therapy has potential therapeutic value for numerous solid tumors and hematological malignancies. Eligibility requires comprehensive evaluation based on cancer type, disease stage, prior treatment history and physical condition. Late-stage diagnosis does not rule out viable treatment options — many multi-line treatment patients choose combined NK regimens as concurrent or maintenance therapy. Final eligibility depends on expert review of full medical records.
Q2. How long does the whole process take from submitting medical records to the first cell reinfusion?
Standard workflow: Preliminary feedback within 24 hours after record submission → Regimen customization upon assessment approval → Approximately 7–14 days for cell isolation and ex vivo expansion → Reinfusion after quality inspection passes. The total timeline varies per individual regimen; full schedules will be clearly notified post-assessment.
Q3. Are cells prepared from my own blood? What about safety standards?
Regimens may use autologous or strictly screened allogeneic cells depending on individual plans. All cell preparation takes place in GMP-grade sterile laboratories. Every batch undergoes flow cytometry testing and third-party independent quality certification before reinfusion, ensuring traceable sources and verifiable quality. Cell source type is determined by personalized treatment plans.
Submit your medical records to receive a personalized professional assessment within 48 hours. Assessments are free with no mandatory treatment obligations. We provide objective, sincere expert guidance to support every patient through their anti-cancer journey.
